Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure by Cao, Hongcui et al.
RESEARCH ARTICLE Open Access
Therapeutic potential of transplanted placental
mesenchymal stem cells in treating Chinese
miniature pigs with acute liver failure
Hongcui Cao
1, Jinfeng Yang
1, Jiong Yu
1, Qiaoling Pan
1, Jianzhou Li
1, Pengcheng Zhou
1, Yanyuan Li
2,
Xiaoping Pan
1, Jun Li
1, Yingjie Wang
1 and Lanjuan Li
1*
Abstract
Background: Stem cell-based therapy to treat liver diseases is a focus of current research worldwide. So far, most
such studies depend on rodent hepatic failure models. The purpose of this study was to isolate mesenchymal stem
cells from human placenta (hPMSCs) and determine their therapeutic potential for treating Chinese experimental
miniature pigs with acute liver failure (ALF).
Methods: hPMSCs were isolated and analyzed for their purity and differentiation potential before being employed
as the donor cells for transplantation. ALF models of Chinese experimental miniature pigs were established and
divided into four groups: no cell transplantation; hPMSCs transplantation via the jugular vein; X-ray-treated hPMSCs
transplantation via the portal vein; and hPMSCs transplantation via the portal vein. The restoration of biological
functions of the livers receiving transplantation was assessed via a variety of approaches such as mortality rate
determination, serum biochemical analysis, and histological, immunohistochemical, and genetic analysis.
Results: hPMSCs expressed high levels of CD29, CD73, CD13, and CD90, had adipogenic, osteogenic, and hepatic
differentiation potential. They improved liver functions in vivo after transplantation into the D-galactosamine-injured
pig livers as evidenced by the fact that ALT, AST, ALP, CHE, TBIL, and TBA concentrations returned to normal levels
in recipient ALF pigs. Meanwhile, histological data revealed that transplantation of hPMSCs via the portal vein
reduced liver inflammation, decreased hepatic denaturation and necrosis, and promoted liver regeneration. These
ameliorations were not found in the other three groups. The result of 7-day survival rates suggested that hPMSCs
transplantation via the portal vein was able to significantly prolong the survival of ALF pigs compared with the
other three groups. Histochemistry and RT-PCR results confirmed the presence of transplanted human cells in
recipient pig livers (Groups III, IV).
Conclusions: Our data revealed that hPMSCs could not only differentiate into hepatocyte-like cells in vitro and in
vivo, but could also prolong the survival time of ALF pigs. Regarding the transplantation pathways, the left branch
of the portal vein inside the liver was superior to the jugular vein pathway. Thus, hPMSCs transplantation through
the portal vein by B-ultrasonography may represent a superior approach for treating liver diseases.
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Acute liver failure (ALF) is defined as the rapid develop-
ment of severe acute liver injury with impaired synthetic
function and hepatic encephalopathy in the absence of
pre-existing liver diseases. The disease carries a high
morbidity and mortality. Orthotopic liver transplantation
is the most effective therapy for ALF, but it is highly
intrusive, irreversible, and limited by a shortage of donor
organs, high expense, and the necessity of lifelong immu-
nosuppressive treatments [1,2]. Stem cell-based therapy,
a promising alternative approach, is currently a focus of
research worldwide [3,4]. Hepatocyte transplantation has
been successfully reported in experimental animals as
well as in some clinical human studies [5,6]. However,
this procedure, which requires a large number of func-
tional hepatocytes, is also restricted by the lack of avail-
able organs for cell isolation [7]. Novel cell sources are
therefore needed to develop and improve the accessibility
of cell-based therapies in hepatology. The preeminent
candidate cells for this purpose are mesenchymal stem
cells (MSCs), which can be obtained from various tissues,
such as bone marrow (BM), muscle, tooth, periodontal
ligament, amniotic fluid (AF), scalp tissue, dermis, pla-
centa, adipose tissue (AT), and umbilical cord blood
(UCB) [8-18]. Furthermore, isolated MSCs are multipo-
tent and can differentiate into multiple lineage cell types
including mesodermal cell lineages such as osteoblast,
adipocyte, chondroblast, myocyte, and cardiomyocyte, as
well as non-mesodermal cells such as hepatocyte and
neurocyte [19]. Besides, MSCs have been demonstrated
to be less immunogenic and can induce tolerance upon
transplantation [20]. Due to their self-renewal capacity,
multilineage differentiation potential and immunosup-
pressive qualities, MSCs are accepted as the most suitable
source for cell-based therapy for liver diseases. Recently,
their therapeutic potential in the treatment of liver injury
has been evaluated. MSCs exhibited the highest potential
for liver regeneration compared with other BM cell sub-
populations in an animal model of hepatic injury [21].
Studies have demonstrated the capacity of bone marrow-
derived mesenchymal stem cells (BM-MSCs) to differ-
entiate into hepatocytes when directly xenografted to
allylalcohol (AA)-treated rat liver [22]. Additionally, Jung
et al. reported that human umbilical cord blood-derived
mesenchymal stem cells (hUCB-MSCs) were able to
ameliorate liver fibrosis in a carbon tetrachloride (CCl4)-
induced cirrhotic rat model [23]. MSCs from human
umbilical cord/adipose tissue also have the potential to
improve liver function in mice with liver injury
[17,24,25]. Another promising source of MSCs is the pla-
centa. MSCs from human placenta (hPMSCs) display
characteristics similar to those of MSCs from bone mar-
row, but enjoy several advantages [26]. They are free of
ethical concerns, non-invasively accessible, abundant,
and strongly immunosuppressive [27-29]. Placenta-
derived cells also display multilineage differentiation
potential and can be differentiated into hepatocyte-like
cells in vitro [30]. Moreover, hPMSCs exert an anti-fibro-
t i ce f f e c ti nar a tm o d e lo ft h eC C l 4-injured liver [31],
and transplanted hPMSCs also ameliorate carbon tetra-
chloride-induced liver cirrhosis in mouse.
However, the therapeutic potential of hPMSCs in a large
animal model of hepatic injury remains largely unexplored.
In the present study, we isolated MSCs from human pla-
centas and characterized their morphology, phenotypic
profiles, growth potency, and capacity to differentiate into
various lineages. MSCs were transplanted directly into
pigs with acute liver failure induced by G-galactosamine
(GalN) via two routes: the jugular or portal veins. The
intra-portal cell transplantation procedure was guided by
B-ultrasonography. After transplantation, their capacity to
overcome hepatic injury was investigated.
Methods
Isolation and culturing of human placental mesenchymal
stem cells (hPMSCs)
Placentas were obtained from donors at the Hangzhou
Red Cross Hospital in China after informed consent had
been obtained. The study used a protocol approved by
the Research Ethics Committee of the First Affiliated
Hospital, School of Medicine, Zhejiang University.
The placental tissue was washed with preheated phos-
phate buffered saline (PBS, pH 7.2 ± 0.1, GenomSciences,
Hangzhou, China), minced, and digested using 0.1% (w/v)
collagenase type IV (Invitrogen, USA) at 37°C for 30 min.
Recovered cells and digested cell debris were filtered
through a 100-μm cell strainer. Mononuclear cells (MNCs)
obtained by lymphocyte isolation (GE Healthcare, Ficoll-
Pague™ PLUS, Sweden) were cultured in special medium
(MesenCult
® Human Basal Medium plus MesenCult
®
Human Supplement, STEMCELL Technologies Inc., Van-
couver, Canada) and adjusted to 2 × 10
6 cells in T25-cm
2
tissue culture flasks (Nunc Flasks Nunclon™Δ with Filter
Cap, Denmark) maintained in an incubator at 37°C in a
humidified atmosphere with 5% (v/v) CO2. Approximately
4 to 6 days later, many colonies had formed. After achieving
60-70% confluence, adherent cells were trypsinized using
0.25% (w/v) trypsin/EDTA (Invitrogen, Carlsbad, CA, USA)
and re-plated at a 1:3 dilution. Placenta-derived cells were
cultured continuously under the same conditions.
Surface antigen expression
Culture-expanded cells (passages 3 to 6) were washed with
PBS-containing 0.5% (w/v) bovine serum albumin (BSA)
and their concentration adjusted to 1 × 10
6 cells/100 μL.
Their surface antigen expression was evaluated by
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coerythrin (PE), CD13-PE, CD133-PE, CD31- allophyco-
cyanin (APC), CD29-APC, CD73-APC, CD105-APC,
CD79B-fluorescein isothiocyanate (FITC), CD34-FITC,
CD166-FITC, and CD45-TRI COLOR (PE-Cy5- PC5)
(eBioscience, Inc., San Diego, CA, USA). After being
labeled with antibodies in the dark at room temperature
for 20 min, cells were washed twice with PBS. Two-color
flow cytometry was conducted using a Beckman Coulter
Cytomics FC 500 MPL (Beckman Coulter, Inc., Los
Angeles, CA, USA), and the data were analyzed using
MXP software.
Differentiation studies
Adipogenic and osteogenic differentiation
Adherent cells derived from placenta (passages 2 to 6)
were plated at a density of 2 × 10
3/well on six-well mul-
tidishes (Nunclon™Δ Surface, Denmark) and cultured
in special conditional adipogenic medium (MesenCult
®
Human Adipogenic Suppl, STEMCELL Technologies,
Inc., Canada) as per the manufacturer’sp r o t o c o l .A f t e r
4 weeks, adipogenesis was confirmed by oil red O stain-
ing (Sinopharm Chemical Reagent Co., Ltd, Shanghai,
China) and lipoprotein lipase (LPL) mRNA detection.
Human intraoperative abandoned adipose tissue and
hPMSCs cultured in normal growth medium served as
controls.
MSCs from placenta (passages 2 to 6) were plated at a
density of 2 × 10
3/well in six- well plates (Nunclon™Δ
Surface, Denmark) and expanded in special conditional
osteogenic medium (OriCell™ hMSC Osteogenic Differ-
entiation Medium, Cyagen Biosciences, Guangzhou,
China) and media was changed twice per week. After 4
weeks, osteogenic differentiation was evaluated by Ali-
zarin Red S staining (Genmed Scientifics Inc., USA,
Shanghai, China) and detection of osteopontin (OPN)
mRNA. hPMSCs cultured in normal growth medium
and immortalized human fetal osteoblastic cells (hFOB
1.19 cell line, Cell Bank of the Chinese Academy of
Sciences, Shanghai, China) served as controls.
Hepatic differentiation
Cultured placental cells (1 × 10
4/mL; passages 2 to 6)
were plated in T25-cm
2 tissue culture flasks (Nunc Flasks
Nunclon™Δ with Filter Cap, Denmark) and four-well
chamber slides (Nunc Lab-Tek™ Chamber Slide™ Sys-
tem, Denmark) with LG-DMEM (Gibco/Invitrogen,
USA) containing 10% (v/v) FBS (Gibco/Invitrogen, USA)
for 2 days. Hepatogenic induction was conducted as fol-
lows. The medium was changed to IMDM supplemented
with 20 ng/mL epidermal growth factor (EGF) and10 ng/
mL fibroblast growth factor (FGF) for 2 days. The cells
were then treated with IMDM with 20 ng/mL hepatocyte
growth factor (HGF), 10 ng/mL FGF, and 0.61 g/L niacin
amide and 1% (v/v) insulin-transferrin-selenium (ITS)
premix (Sigma-Aldrich, St Louis, MO, USA) for 10 days;
the medium was changed every 3 days. Finally, cells were
maintained in IMDM containing 20 ng/mL oncostatin M
( O S M ;S tL o u i s ,M O ,U S A ) ,1μmol/L dexamethasone
( D e x ;S i g m a - A l d r i c h ,S tL o u i s ,M O ,U S A ) ,a n d1 %( v / v )
ITS premix for 10 days. For the next few days, cells were
cultured with HEPATOZYME-SFM (Gibco/Invitrogen,
USA). Cells cultured with low glucose DMEM (LG-
DMEM) containing 10% (v/v) FBS served as controls.
Albumin (ALB), alpha-fetoprotein (AFP), cytokeratin 18
(CK18), and cytokeratin 19 (CK19) levels were deter-
mined by immunohistochemistry and RT-PCR; and urea
synthesis, low-density lipoprotein (LDL) uptake, glycogen
storage, and cytochrome P450(CYP450) enzymatic activ-
ity were assayed to evaluate hepatogenic induction on
days 7, 14, 21, 28, and 35 after induction.
Immunocytochemistry
Cell samples were fixed in 4% (v/v) paraformaldehyde
solution at room temperature for 15 min. After being
treated with 0.3% (v/v) hydrogen peroxide (H2O2)a n d
blocked in 5% (m/v) BSA, cells were incubated with
diluted primary antibody against anti-human CK18
(2 mg/mL, 1:400; Abcam, UK), human AFP (1:200;
Abcam, UK), human CK19 (1:400; Abcam, UK), and
human ALB (5 mg/mL, 1:500; Abcam, UK), according
to the manufacturer’s instructions. The primary anti-
body was detected using horseradish peroxidase-conju-
gated anti-rabbit IgG (1 mg/mL, 1:1,000; Abcam, UK)
antibody followed by incubation with diaminobenzidine
tetrahydrochloride solution (DAB kit, Vector Labs, Bur-
lingame, CA, USA). Cultured human hepatocytes served
as positive controls.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA of cells was extracted with the Trizol reagent
(Invitrogen, USA). The quantity and purity of RNA were
estimated by reading absorbance at 260 and 280 nm.
cDNA was synthesized using oligo dT primers with the
Improm-II™ Reverse Transcription System (Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. The primers for the target products were
designed as in Table 1. Polymerase chain reactions (PCR)
were carried out in a PCR thermal cycler (Thermo Hybaid,
Waltham, MA, USA). PCR products were electrophoresed
on a 1.2% (m/v) agarose gel containing 0.5 μg/mL ethidium
bromide for nucleic acid visualization under UV light.
Glycogen storage staining
Primary human hepatocytes were obtained from the Key
Lab of Combined Multi-organ Transplantation, Ministry
of Public Health, P. R. China.
Undifferentiated and differentiated hPMSCs and pri-
mary human hepatocytes (5 × 10
5/well) were plated in
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mented with 10% (v/v) FBS or HEPATOZYME-SFM (all
from Gibco/Invitrogen, USA). Cells were stained with
the periodic acid-Schiff (PAS) staining kit according to
the manufacturer’s protocol (Genmed Scientifics Inc.,
Shanghai, China).
Low-density lipoprotein (LDL) uptake assay
Undifferentiated and differentiated hPMSCs and primary
human hepatocytes (5 × 10
5/well) incubated in DMEM
containing 10% (v/v) FBS were labeled with DiI-LDL
(1,19-dioctadecyl-3,3,39,39-tetramethylllindocarbocyane-
low-density lipoprotein, Molecular Probes, Invitrogen,
U S )a t1 0μg/mL for 24 h at 37°C. Cells were harvested,
washed with cold PBS, and then stained according to the
manufacturer’s protocol. Uptake was subsequently evalu-
ated by fluorescence microscopy (Olympus IX81, Japan).
Urea assay
Undifferentiated and differentiated hPMSCs and primary
human hepatocytes (5 × 10
5/well) were cultured for 24 h
in HepatoZYME-SFM (serum-free, no phenol red,
Gibco
®, Invitrogen™, USA) supplemented with 0.9 mmol/
L ammonium chloride (NH4Cl, Bio Basic Inc., NY, USA).
Supernatants were collected, centrifuged, and urea levels
were measured in 96-well plates (Nunclon™Δ Surface,
Denmark) at 430 nm by a spectrophotometer (Beckman
Coulter
® Multimode Detector DTX880, Beckman Coulter,
Inc.), according to the instructions of the QuantiChrom™
urea assay kit (DIUR-500, BioAssay Systems, CA, USA).
Determination of cytochrome P450 activity
Undifferentiated and differentiated hPMSCs and primary
human hepatocytes (5 × 10
5/well) were plated in six-well
plates and cultured in either LG-DMEM supplemented
with 10% (v/v) FBS or HEPATOZYME-SFM (all from
Gibco/Invitrogen, USA), both with 10 μMr i f a m p i c i nf o r
48 h. The media were then changed to IMDM containing
a luminogenic CYP substrate (luciferin-PFBE, 50 μM, 1:40
dilution) for 24 h. Intracellular CYP enzyme activities were
assessed by assaying luciferin production, according to the
manufacturer’s instructions (P450-Glo™ CYP3A4 assay
with leciferin-PFBE, Promega, USA). Luciferase activity
was expressed as relative luminescence units (RLU).
hPMSCs irradiation
hPMSCs from the placenta (passages 3 to 6) were seeded
in T175-cm
2 tissue culture flasks (Nunc Flasks Nun-
clon™Δ with Filter Cap, Denmark). After achieving
70-80% confluence, cells were irradiated with 30 Gy at
room temperature using six MV X-rays (500 Mu/min,
total of 2890 Mu) from a Varian 23EX Linear Accelerator.
Cell-viability assay
The lethal effect of irradiation on hPMSCs was deter-
mined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Each group of cells
was seeded at a density of 3000 cells per well in 96-well
plates (Nunclon™Δ Surface, Denmark). After irradiation
for 0, 24, 48, 72, 96, 120, or 144 h, 20 μL of MTT reagent
(5 mg/mL, Sigma-Aldrich) was added to each well, and
cells were incubated for 4 h at 37°C and 5% (v/v) CO2.
The formazan complex was dissolved in 150 μL dimethyl-
sulphoxide (DMSO, Sigma-Aldrich), and absorbance at
490 nm was measured using a spectrophotometer (Beck-
man Coulter
® Multimode Detector DTX880, Beckman
Coulter, Inc.). Experiments were performed in triplicate
and repeated at least three times. In cell growth curves,
the optical density (OD) values were plotted as a function
of elapsed time.
Cell-cycle and apoptosis analysis
The effect of irradiation on cell-cycle progression and
apoptosis of hPMSCs was investigated by flow cytometry
(Beckman Coulter, Inc.). Cell-cycle and apoptosis ana-
lyses were carried out at 0 and 6 h and at 3 and 7 days
Table 1 Primers and conditions used for RT-PCR
Primer Sequence Amplicon size (bp) Cycle
ALB 5’- CACAGTTGCAACTCTTCGTGAAAC-3’
5’- AGCAGTGCACATCACATCAACC-3
154 94°C/30 s; 55°C/40 s; 72°C/60 s
CK18 5’- CACCGTCGTCCGCAAAGCCT-3’
5’- CCTGCCAGACCCCCGGCTAT-3
269 94°C/30 s; 58°C/40 s; 72°C/60 s
CK19 5’-AGGTGGATTCCGCTCCGGGCA-3’
5’- ATCTTCCTGTCCCTCGAGCA-3’
460 94°C/60 s; 64°C/60 s; 72°C/120 s
AFP 5’- GCATGTGCAGTAATGAAAAAT-3’
5’- GAACAAAACTTGCCAAGAAGAT-3’
400 94°C/30 s; 50°C/40 s; 72°C/60 s
b-actin 5’- GAGCGGGAAATCGTGCGTGACATT-3’
5’- GATGGAGTTGAAGGTAGTTTCGTG-3’
234 94°C/30 s; 58°C/40 s; 72°C/60 s
LPL 5’-ATGGAGAGCAAAGCCCTGCTC-3’
5’-TACAGGGCGGCCACAAGTTTT-3’
298 94°C/30 s; 56°C/30 s; 72°C/60 s
OPN 5’-CTAGGCATCACCTGTGCCATACC-3’
5’-CTAGGCATCACCTGTGCCATACC-3’
330 94°C/30 s; 55°C/45 s; 72°C/60 s
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were fixed with pre-cooled absolute ethanol (-20°C) and
finally stained using a cell-cycle staining kit (Multi-
Sciences, Hangzhou, China), according to the manufac-
turer’s protocol. The distribution of cell-cycle phases
with different DNA contents was determined by flow
cytometry and analyzed using multicycle ANOVA analy-
sis software. Cell-apoptosis analysis was carried out by
flow cytometry using the Annexin V/PI apoptosis kit
(MultiSciences, Hangzhou, China). The percentages of
apoptotic cells were analyzed using MXP cytometer
software. Experiments were repeated three times.
D-galactosamine-induced acute liver-failure (ALF) model
Male Chinese experimental miniature pigs weighing 10-12
kg were obtained from Beijing Agriculture University
(Beijing, China). Animal procedures were approved by the
Animal Ethics Committee of Zhejiang University. All pigs
were housed in an air-conditioned room with a 12 h dark/
l i g h tc y c l ea n dr e c e i v e dh u m a n ec a r ef o rt h ed u r a t i o no f
the study. For catheterization through the external jugular
vein, ketalar (0.2 mL/kg) (Fujian Gutian Pharmaceutical
Co., Ltd., Fujian, China) was injected intramuscularly to
induce sedation. An auricular vein was secured and
2.5 mg/kg/h diprivan (AstraZeneca, Caponago, Italy)
administered to achieve continuous anaesthesia. Catheteri-
zation was performed as described previously [32]. Six
hours after the operation, acute liver injury in the pigs was
induced by administration of D-galactosamine (GalN,
Hanhong Chemical Co., Ltd, Shanghai, China) in 5% (w/v)
g l u c o s e( p H6 . 8 )a tad o s eo f1 . 5g / k gb o d yw e i g h tv i aa
venous catheter. Ultimately, all pigs without cell transplan-
tation died due to GalN-induced hepatic failure, making
sacrifice unnecessary. GalN-induced liver injury was iden-
tified histologically by a trained pathologist. Animals were
considered to be dead when their heartbeat and breathing
ceased and blood pressure could not be measured.
Experimental groups and cell transplantation
Twenty-four ALF pigs were randomly divided into four
groups (n = 6 each): Group I, ALF pigs without cell trans-
plantation; Group II, hPMSCs transplantation via the
jugular venous catheter; Group III, X-ray-treated hPMSCs
transplantation via the portal vein; and Group IV, hPMSCs
transplantation via the portal vein.
Eighteen hours after GalN administration, hPMSCs
(passages 3 to 6; 1.0 × 10
8 in 5 mL saline) were directly
transplanted into the pigs via the jugular venous catheter
or the portal vein. For intra-portal cell transplantation, an
18 G PTC needle (Hakko Co., Chikuma-Shi, Japan) with a
guide wire was inserted into the left branch of the portal
vein inside the liver. The procedure was performed under
general anesthesia and guided by color ultrasound
(Sequoia 512, Siemens, Germany). By injecting contrast
medium SonoVue (Bracco, Milan, Italy), the transplanted
cells were seen to be distributed throughout the liver.
When the guide wire was withdrawn, blood flow con-
firmed that the portal vein had been accessed. Then, the
hPMSCs preparation was directly and slowly infused into
the liver via the portal vein over about 5 min. For jugular
vein cell transplantation, the same number and volume of
hPMSCs were infused into the jugular vein via a venous
catheter. All transplanted pigs were immunosuppressed by
daily administration of dexamethasone (Hubei Tianyao
Pharmaceutical Co., Ltd, Xiangfan, Hubei) (10 mg/kg/d)
during the first week after the transplantation. Blood sam-
ples were collected for biochemical analysis at the follow-
ing time points: pre-and post-GalN administration (18 h),
1 to 7 days after cell infusion, then every 2 weeks from the
second week until death. Liver samples from surviving ani-
mals were harvested every 2 weeks post-transplantation
using an automatic biopsy needle, and the livers of dead
animals were directly removed by dissection. These liver
tissues were immediately stored at -80°C for molecular
detection or fixed in 10% (v/v) formalin for histological
and immunohistochemical analysis.
Biochemical analysis
Blood samples were obtained from each pig and centri-
fuged for 10 min at 1751 × g (Sorvall
® Biofuge Stratos,
Thermo, Germany) and serum was collected. Concen-
trations of liver injury markers, such as alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALP), total bilirubin(TBIL), and
total bile acids (TBA) were measured with an automated
biochemical analyzer (Abbott Aeroset, Abbott Labora-
t o r i e s ,C h i c a g o ,I L ,U S A ) .A l ls a m p l e sw e r er u ni n
triplicate.
Cytokine level measurement
Supernatants of hPMSCs (passages 3 to 6), hPMSCs co-
cultured with 1 × 10
6 lymphocytes from healthy donors
for 24 h and serum from model pigs, were collected,
centrifuged, and leukemia inhibitory factor (LIF) levels
were analyzed using a human LIF platinum ELISA Kit
(eBioscience, Inc., San Diego, CA, USA). Tests were per-
formed according to the manufacturer’sp r o t o c o la n d
every sample was run in duplicate. LIF concentration
(pg/mL) was determined by comparison with the stan-
dard curve.
hPMSCs (1 × 10
6) and their supernatants were co-cul-
tured with PBMC (1 × 10
6) for 24 h. Interferon-g (IFN-
g) secretion was then assayed by ELISpot, according to
the manufacturer’s instructions (human IFN-g ELISpot
P R Ok i t ,M A B T E C HA B ,S w e d e n ) .T h er e s u l t i n gs p o t s
were counted and analyzed using a computer-assisted
AID ELISPOT Reader System (Immun Spot
®,C e l l u l a r
Technology Ltd.).
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Pig livers were harvested at the indicated time points after
cell transplantation, fixed in 10% (v/v) formalin, and
embedded in paraffin. Sections (5-μm thickness) were
deparaffinized, rehydrated, and stained with hematoxylin
and eosin (H&E) for routine histology. For immunohisto-
chemical evaluation, the sections were heated in citrate
buffer (0.02 mol/L, pH 5.8) for antigen retrieval. Endogen-
ous peroxidase was prevented by immersion in a 0.3%
(v/v) hydrogen peroxide (H2O2)i nm e t h a n o lb a t hf o r
15 min. After washing, non-specific binding was blocked
with 5% (m/v) bovine serum albumin in PBS. Sections
were then incubated with diluted primary antibody against
anti-human ALB (5 mg/mL, 1:5,000; Abcam, UK), human
AFP (1:250; Abcam, UK), and human CK18 (1 mg/mL,
1:200; Abcam, UK), according to the manufacturer’s
instructions. Detection of primary antibody was performed
using horseradish peroxidase-conjugated secondary anti-
bodies (1 mg/mL, 1:1,000; Abcam, UK). Peroxidase activity
was revealed by a 3 to 5 min exposure to diaminobenzi-
dine tetrahydrochloride solution (DAB kit, Vector Labs).
The sections were then washed, counterstained with
hematoxylin for one minute, mounted, and observed
under a light microscope (TE2000, Nikon, Japan). Normal
human tissue obtained under informed consent served as
positive controls.
Detection of human alu sequences by PCR
PCR for human alu sequences was performed to confirm
the presence of transplanted hPMSC-derived cells in reci-
pient pig livers. Total DNA of liver samples was extracted
with a DNeasy
® Blood & Tissue Kit (Qiagen, Hilden, Ger-
many), according to the manufacturer’s instructions. The
primers used were 5’-CTGGGCGACAGAACGAGATTC-
TAT-3’ and 5’-CTCACTACTTGGTGACAGGTTCA-3’;
samples were incubated at 94°C for 2 min and then ampli-
fied for 35 cycles of denaturation for 30 s at 94°C, anneal-
ing for 30 s at 60°C, and extension for 59 s at 72°C. The
PCR products were analyzed by resolution on a 1.2% (w/v)
agarose gel and visualized by ethidium bromide staining.
Images were captured using a gel documentation system
(Syngene GBox-HR Gel Doc System, UK).
Statistical analysis
Data were presented as the mean ± standard deviation
(SD). Differences in serum levels of biochemical para-
meters were analyzed using a paired-samples t-test. Statis-
tical evaluations of cell viability, cell-cycle distribution, and
percentage apoptosis, urea synthesis, CYP-450 enzymatic
activity, LIF, and IFN-g secretion were performed using a
t-test. Animal survival was analyzed using the Kaplan-
Meier log rank method. Values of P <0 . 0 5w e r ec o n s i d -
ered statistically significant. Data were analyzed with SPSS
ver. 16.0 statistical software (SPSS, Inc., Chicago, IL, USA).
Results
Morphology and phenotype profiles of hPMSCs
Primary adherent monolayer placental cells formed
many colonies after 4 to 6 days and exhibited a fibro-
blastic morphology. They were subcultured every 3 to 4
days (Figure 1).
The immunophenotype of culture-expanded cells
(passages 3 to 6) was analyzed by flow cytometry,
which revealed that the cells expressed high levels of
CD29 (100%), CD73 (95.3%), CD13 (100%), and CD90
(85.2%), moderate levels of CD105 (69.4%) and CD166
(44.1%), but expressed almost no hematopoietic cell
markers such as CD45 (0.1%), CD34 (0.5%), and
CD133 (0.2%). CD31 and CD79b were expressed in
only 0.2 and 0.4% of the population, respectively (Fig-
u r e2 ) .T h e s ef i n d i n g sa r ec o nsistent with the general
description of the phenotype profile of classical
hPMSCs, confirming that the cells were of the MSC
lineage, but not hematopoietic cells.
Adipogenic differentiation potential of hPMSCs
hPMSCs were cultured for 4 weeks in adipogenic med-
ium, and adipogenic differentiation was assessed by oil
Figure 1 hPMSCs morphology (4×).( A) Three days after isolation from the placenta before changing media; (B) four days after isolation from
the placenta after changing media; (C) four weeks after isolation (passage 6).
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Page 6 of 20red O staining and LPL mRNA detection. Differentiated
hPMSCs formed intracytoplasmic lipid droplets and
c o u l db ei d e n t i f i e db yo i lr e dOs t a i n i n g ,w h e r e a s
hPMSCs cultured in normal growth medium had no
lipid droplets and exhibited negative staining. Human
adipose tissue (positive control) exhibited large lipid
vesicles (Figure 3A, B, and 3C). Adipogenic differentia-
tion of hPMSCs was further confirmed by expression of
adipocyte-specific genes (LPL), as determined by RT-
PCR (Figure 3H).
Figure 2 Phenotype profile of adherent cells obtained from placentas. Immunophenotype of hPMSCs determined by flow cytometry at
passage three using labeled antibodies specific for the indicated human surface antigens or negative controls.
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Page 7 of 20Osteogenic differentiation potential of hPMSCs
hPMSCs were cultured for 4 weeks in osteogenic medium,
and osteogenic differentiation was assessed by Alizarin
Red S staining and bone-specific gene (OPN) mRNA
detection. Differentiated hPMSCs and osteoblast formed
bone nodules and stained positive, whereas hPMSCs cul-
tured in normal growth medium showed no positive stain-
ing (Figure 3D-G). Osteogenic differentiation of hPMSCs
was further confirmed by OPN expression, as determined
by RT-PCR (Figure 3I).
Hepatic differentiation potential of hPMSCs
hPMSCs at passage three were cultured in differentiation
medium with hepatogenic supplements for 3 weeks. Dif-
ferentiation efficiency was evaluated at the protein and
mRNA levels. Immunocytochemistry revealed the pre-
sence of hepatic markers (ALB, AFP, CK18, CK19) in
hPMSCs subjected to the hepatogenic differentiation
protocol as well as in hepatocytes, but not in undifferen-
tiated cells (Figure 4A). Similar results were obtained by
RT-PCR analysis (Figure 4B), which revealed the expres-
sion of ALB, AFP, CK-18, and CK-19 mRNA by these dif-
f e r e n t i a t e dc e l l s .N oa m p l i fication occurred in hPMSCs
cultured in the absence of hepatogenic inducers.
Hepatocyte-like cells differentiated from hPMSCs
exhibited characteristics typical of hepatocytes such as
LDL uptake, glycogen storage, urea synthesis, and CYP-
450 enzymatic activity, which were absent in undifferen-
tiated MSCs (Figure 5). Primary human hepatocytes
served as a positive control.
Effect of X-ray irradiation on the viability and cell-cycle
progression of hPMSCs
To investigate the effect of X-ray irradiation on the viabi-
lity of hPMSCs, MTT assays were performed and a cell
growth curve generated. No increase in cell numbers was
Figure 3 Adipogenic (A-C, H) and osteogenic (D-G, I) differentiation of hPMSCs.( A) hPMSCs maintained in normal growth medium (10×);
(B) human adipose tissue as a positive control (10×); (C) hPMSCs that had undergone adipogenic differentiation (accumulation of lipid droplets
shown by red staining) (20×); (D) hPMSCs maintained in normal growth medium; (E) osteoblast as a positive control(4×); (F, G) hPMSCs that had
undergone osteogenic differentiation (bone nodules formed), before and after staining (4×). (H, I) Representative RT-PCR analyses of hPMSCs
cultured in adipogenic and osteogenic medium for 28 days. No LPL expression was found in hPMSCs maintained in regular medium (H, lane 2).
After adipogenic induction, hPMSCs expressed LPL mRNA (H, lane 1). Human adipose tissue expressed LPL mRNA (H, lane 3). No OPN expression
was found in hPMSCs maintained in growth medium (I, lane 2). After osteogenic induction, hPMSCs expressed OPN mRNA (I, lane 1). Osteoblasts
expressed OPN mRNA (I, lane 3). LPL, lipoprotein lipase; OPN, osteopontin.
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Page 8 of 20found in hPMSCs treated with X-rays (Figure 6), suggest-
ing a lethal effect. In contrast, a significant increase in
cell number was observed in normal hPMSCs, which
continued to increase until the plateau phase. These data
suggest that X-ray irradiation can compromise the viabi-
lity of hPMSCs.
To assess the effects of X-ray irradiation on cell-cycle
progression and apoptosis, flow cytometry was utilized.
Compared to normal hPMSCs (G1,8 7 . 4 % ;S ,6 . 8 7 % ;G 2/M,
5.8%), 89.3% of X-ray treated cells (7 days post-treatment)
were in G1 phase, 10.7% in S phase, and 0% in G2/M
phase (Figure 7). These data suggest that X-rays can arrest
hPMSCs in G1 phase. Treatment with X-rays also resulted
in significant apoptotic responses. The percentage of
apoptotic cells was 1.26% in the normal hPMSCs group; 7
days after treatment with X-ray, it increased to 72.34%.
These findings reveal that X-rays can significantly induce
hPMSCs apoptosis. Taken together, our data suggest that
X-ray irradiation dramatically blocked cell cycle progres-
sion and induced apoptosis of hPMSCs.
Survival of ALF pigs transplanted with hPMSCs
In Group I, all pigs died within 6 days (survival time,
94.7 ± 15.4 h); in Group II, all pigs died within 4 days
( s u r v i v a lt i m e ,6 7±2 2 . 5h )e x c e p to n e( s a c r i f i c e da t3
months); in Group III, four pigs died within 6 days
(survival time, 75.8 ± 48.0 h) and two others were
sacrificed at 3 months; in Group IV, two pigs died
after 7 days (survival time, 135 ± 33.9 h) and four
were sacrificed at 5 months. In Groups I to IV, 7-day
survival rates were 0, 16.7, 33.3, and 66.7%, respec-
tively. The survival of pigs in Group IV was prolonged
significantly compared with the other three groups
(P < 0.05; Figure 8).
Figure 4 Hepatic differentiation of hPMSCs.( A) Immunocytochemistry analysis of hepatically differentiated or undifferentiated hPMSCs. (A, D,
G, and J) Staining for the hepatic markers ALB, AFP, CK18, and CK19; a large number of cells had a light-brown coloration. (B, E, H, and K)
hPMSCs cultured in growth medium did not display positive immunocytochemical staining. (C, F, I, and L) Efficiency of immunocytochemical
staining was tested on cultured hepatocytes as positive controls (10×). (B) RT-PCR analysis of hepatic-specific gene expression in hepatically
differentiated or undifferentiated hPMSCs. Lane 1, hPMSCs that had undergone hepatic differentiation; lane 2, hPMSCs cultured in growth
medium; and lane 3, human liver tissue as a positive control.
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Page 9 of 20Restoration of liver functions in ALF pigs transplanted
with hPMSCs
B i o c h e m i c a lp a r a m e t e r s( A L T ,A S T ,A L P ,C H E ,T B I L ,
and TBA) were measured at selected time points to
determine the restoration of liver functions in ALF pigs
transplanted with hPMSCs (Figure 9). The serum levels
of these factors in Groups I, II, and III were significantly
increased 1 to 3 days after GalN-induced injury, and
remained high until death. These parameters in Group
IV pigs also increased initially but then decreased
gradually from day 4 and were approaching normal
levels one week after cell transplantation. The biochem-
ical analyses revealed significant differences between
pre- and post-GalN treatment in all four groups, sug-
gesting that the ALF pig models were successfully gen-
erated. Also, in Group IV, the differences in these
parameters were significant between days 7 and 2 post
cell transplantation (P < 0.05), indicating that hPMSCs
transplanted via the portal vein significantly recovered
GalN-induced liver damage.
Figure 5 Functional parameters of hepatocyte-like cells differentiated from hPMSCs.( A-D): glycogen storage capacity. (A) Primary human
hepatocytes as a positive control (10×); (B) hPMSCs cultured in normal growth medium did not display positive PAS staining (4×); (C, D)
hPMSCs cultured in hepatogenic differentiation medium for 28 days were positively stained, revealing cytoplasmic glycogen accumulation (C, 4×;
D, 10×). (E-H) LDL uptake. (E) Primary human hepatocytes served as a positive control (10×); (F) hPMSCs maintained in growth medium were
stained negatively; (G, H) LDL uptake was detected in hepatocyte-like cells 21 days after differentiation (G, 10×; H, 20×). (I) urea synthesis assay.
After hepatogenic differentiation culture for 28 days, urea levels in culture supernatants were significantly increased. (J) CYP-450 enzymatic
activities were determined. After hepatogenic differentiation culture for 35 days, CYP-450 enzymatic activity was significantly higher. Data are
mean ± SD (n = 4, *P < 0.05). But urea synthesis and CYP3A4 enzymatic activities of the hepatocyte-like cells derived from hPMSCs were
significantly lower than those of the primary human hepatocytes (**P < 0.01).
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hPMSCs
To determine the immunoregulatory activity of hPMSCs,
human LIF and IFN-g were detected in the sera of model
pigs and hPMSCs supernatants. In the four long-term
survivors of Group IV, human LIF in the serum peaked
on day 4 and then returned to normal (Figure 10A). The
results of Groups I to III were irregular. After hPMSCs
were co-cultured with PMBCs for 24 h, LIF exhibited a
nine-fold increase (663.6 pg/mL) in hPMSCs/PBMCs as
compared to hPMSCs alone.
ELISpot assay revealed that hPMSCs themselves did
not secret IFN-g, but they could stimulate PBMCs to
secret IFN-g (Figure 10B).
Therefore, hPMSCs may contribute to therapeutic
effects in ALF models through immunoregulation.
Figure 6 Effects of X-ray irradiation on hPMSCs viability.C e l l s
were treated with X-rays for the times indicated, and their viability
was measured by MTT assay. OD indicates optical density at 490 nm.
Figure 7 Effects of X-ray irradiation on cell-cycle progression and apoptosis of hPMSCs. Cells were irradiated with X-rays for the times
indicated, and cell-cycle progression and apoptosis were analyzed by flow cytometry. (A) Representative cell-cycle profile of hPMSCs. (B)
Cytograms of hPMSCs apoptosis assays. (C, D) Quantitative analyses of the FACS data. Data are presented as means ± SD of triplicate
experiments; *P < 0.05, **P < 0.01.
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Page 11 of 20Histological features of the ALF pig livers transplanted
with hPMSCs
Livers from each group were collected at selected time
points and H&E staining was performed to examine
liver pathology. Galactosamine-induced liver injury in
the control group (Group I) was indicated by large areas
of inflammation, hepatocyte denaturation, and necrosis,
as well as sinusoid congestion and hemorrhage (Figure
11A). Transplantation of hPMSCs via the portal vein
(Group IV) had a beneficial effect on recovery of the
GalN-injured liver (Figure 11E-L). A visible amelioration
was found in Group IV 4 days after infusion of hPMSCs
(Figure 11F); this was confirmed by milder damage and
lighter lesions. Hemorrhage was markedly decreased.
Hepatocyte denaturation andn e c r o s i sw e r ea l s os u p -
pressed, accompanied by visible liver regeneration.
Furthermore, these effects became more prominent over
time. Hepatocyte denaturation and necrosis and hemor-
rhage disappeared beginning 7 days after transplanta-
tion, and the impaired hepatic lobule returned to a
nearly normal architecture (Figure 11G-L). X-ray-treated
hPMSCs also exerted a beneficial effect on recovery of
the GalN-injured liver, promoting liver regeneration
(Figure 11C) and lobular architecture recovery (Figure
11D). However, no significant improvement was seen in
terms of hepatocyte denaturation and necrosis
and hemorrhage (Figure 11C and 11D). No such
amelioration was found in non-transplanted pigs (Group
I) or in pigs transplanted with normal hPMSCs via the
jugular vein (Group II) (Figure 11A and 11B).
Fate of transplanted hPMSCs in ALF pig livers
To investigate whether hPMSCs are capable of engraft-
ing and undergoing hepatic differentiation in vivo, liver
specimens taken from surviving animals (Group IV)
were examined for the expression of the liver specific
markers, ALB, AFP, and CK18, by immunohistochemis-
try of serial sections. As shown in Figure 12, ALB
expression was only detected at the sixth week after
hPMSCs infusion, showing single spotty positivity stain-
ing in the specimen harvested using an automatic biopsy
needle. ALB
+or CK 18
+cells were observed in three of
the four pigs sacrificed at 5 months, and a small cluster
of cells with more intense staining was detected in one
liver. However, no positive staining for CK18 was
observed in any liver biopsy specimen. Most ALB
+ or
CK18
+cells were located in close proximity to vascular
structures. Additionally, expression of human AFP, a
marker of hepatic progenitor cells, was also investigated
by immunohistochemistry. We were, however, unable to
find even a single human AFP-expressing cell in
hPMSCs-transplanted pigs (data not shown). Liver sec-
tions from Group I (non-transplanted pigs) were com-
pletely negative for ALB, AFP, and CK18 staining
(Figure 12).
Similar results were obtained by RT-PCR analysis
using human-specific primers. A 154-bp albumin band
and a 269-bp CK18 band were detected in sixth-week
liver biopsy specimens (in one of four pig samples) as
well as three pigs sacrificed at 5 months (in three of
four samples). Again, human AFP mRNA was not
detectable by RT-PCR in the livers from hPMSCs-trans-
planted pigs, confirming the results obtained by immu-
nohistochemistry. No expression of human albumin,
AFP, or CK18 transcript was detected in non-trans-
planted pig livers (Figure 13A).
To identify transplanted human cells in recipient pigs,
genomic DNA was extracted from recipient livers, and
human-specific alu repeat sequences were amplified by
PCR (Figure 13B). On the second day following cell
injection, weak expression of human alu sequences was
observed in Group IV (lane 2), which was enhanced on
day 4 (lane 3). This human gene mark was expressed at
a high level beginning on day 7 (lane 4), followed by
continuous expression up to 156 days (lanes 5 and 6).
Weak expression of this gene was also detected in
Group III 1 day after cell transplantation (lane 7), but
became undetectable beginning on day 3 (lane 8). There
w a sn oe v i d e n c eo fe x p r e s s i o na ta n yt i m ep o i n ti n
Groups I and II (lanes 9, 10, and 11).
Figure 8 Survival curves of the four groups. Group I: injured,
non-transplanted; Group II: injured, transplanted with normal
hPMSCs via the jugular vein; Group III: injured, transplanted with X-
ray-treated hPMSCs via the portal vein; Group IV: injured,
transplanted with normal hPMSCs via the portal vein. The survival
rate of Group IV was prolonged significantly compared with the
other three groups (P < 0.05).
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Page 12 of 20Figure 9 Biochemical analyses.( A) Alanine aminotransferase (ALT); (B) aspartate aminotransferase (AST); (C) alkaline phosphatase (ALP); (D)
cholin esterase (CHE); (E) total bile acids (TBA); (F) total bilirubin (TBIL). Group I: injured, non-transplanted; Group II: injured, transplanted with
normal hPMSCs via the jugular vein; Group III: injured, transplanted with X-ray-treated hPMSCs via the portal vein; Group IV: injured, transplanted
with normal hPMSCs via the portal vein. Data are presented as means ± SD. The dotted line represents serum biochemical results of surviving
pigs in Groups II and III.
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According to the International Society for Cellular Ther-
apy (ISCT), MSCs are defined by their expression of
CD105, CD73, and CD90 and lack of expression of
CD45, CD34, CD14 or CD11b, CD79a or CD19, and
HLA-DR. Additionally, they usually differentiate to
osteoblasts and adipocytes in vitro [33]. These data were
based on plastic-adherent cells isolated from BM and
some other tissues. Our data revealed that besides hav-
ing adipogenic and osteogenic differentiation potential
in vitro, MSCs from the placenta expressed high levels
of CD73, CD90, CD13, and CD29, but not hematopoie-
tic cell markers such as CD45, CD34, and CD133. The
different phenotype profiles of MSCs from the BM and
placenta indicates the difference in their biological prop-
erties. Also, hPMSCs had hepatic differentiation poten-
tial in vitro, characterized by the expression of ALB,
AFP, CK18, and CK19, production of urea, glycogen sto-
rage, and LDL uptake. MSCs from the placenta may be
an excellent source for liver disease therapeutics because
they are obtained easily, exhibit a wide variety of favor-
able properties, and can be expanded on a large scale
[26,30,34,35].
Comparing with primary human hepatocytes, hepato-
cyte-like cells derived from hPMSCs showed much lower
levels of LDL uptake and CYP-450 enzymatic activity.
Since hepatocytes in intact liver are maintained in a
three-dimensional environment and supported by sur-
rounding cells such as Kupffer cells and liver endothelial
cells, even primary hepatocytes will quickly lose activities
during routine two-dimensional in vitro culture [36], it is
therefore no surprise that the hPMSCs-derived hepato-
cyte-like cells cultured under similar conditions exhibited
suboptimal hepatic activities. Nevertheless, our data
clearly demonstrated the hepatogenic potential of
hPMSCs that were employed for transplantation.
Currently, rodent models, including rat and mouse, are
used to evaluate the potential of MSCs from the BM and
Figure 10 Levels of human LIF and IFN-g.( A) LIF curve in the serum of Group IV pigs; (B) LIF was markedly increased after hPMSCs were co-
cultured with PMBCs for 24 h. **P < 0.01; (C, D) hPMSCs stimulated PBMCs to secret IFN-g. Each spot represents one human IFN-g secreting cell.
Spots were counted using ImmunoSpot ver. 5.0.3. The spots of the positive control were too numerous to count (TNTC). *P < 0.05, **P < 0.01.
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Page 14 of 20placenta in repairing liver damage [37-41]. To explore the
clinical value of hPMSCs, we used Chinese miniature pigs,
a representative mammal, to establish a liver-failure model
by D-galactosamine administration. The survival rate was
significantly higher in the transplantation group than in
the control group (66.7 vs. 0%). Additionally, the ALT,
AST, ALP, CHE, TBIL, and TBA levels were significantly
decreased in the transplantation group. To determine if
hPMSCs moved to the injured pig livers had differentiated
into hepatocyte-like cells, expression of hepatocyte-specific
markers, such as ALB, AFP, and CK18, was investigated by
immunohistochemistry and RT-PCR. Clusters or scattered
cells positive for human albumin and CK18 were observed
in recipient pig livers, particularly at 5 months after
hPMSCs infusion. However, only positive staining for
human ALB was observed in all liver biopsy specimens 6
weeks post-transplantation. RT-PCR analysis yielded simi-
lar results. In addition, AFP, a marker of immature liver
progenitor cells, was detected by neither immunohisto-
chemistry nor RT-PCR in livers from all hPMSCs recipient
pigs. This may have been due to a limitation of the sam-
pling method: because only a small quantity of biopsied
liver samples was attainable, the probability of detecting
colonized hPMSC-derived cells in these samples was low.
To verify that the observed effects were caused by trans-
planted hPMSCs but not the transplantation procedure
per se or other processes, we further exposed hPMSCs to
a lethal dose of X-rays (30 Gy) and transplanted them into
Chinese miniature pigs as a control for transplanted cells.
MTT and cell-cycle tests revealed that the viability and
proliferation rate of hPMSCs after irradiation were signifi-
cantly decreased; the percentage of G2 cells decreased
from 5.76% to 0%. At the same time, the apoptosis rate of
hPMSCs increased from 1.26% (no irradiation) to 3.7% (6
h after irradiation), 42.41% (3 days after irradiation), and
72.34% (7 days after irradiation). The survival rate of pigs
receiving irradiated hPMSCs was significantly lower than
that of pigs receiving non-irradiated hPMSCs (33.3% vs.
66.7%) but significantly higher than pigs without hPMSCs
transplantation (33.3% vs. 0%). The following possible
mechanisms may account for the observed effects of
hPMSCs transplantation: (1) The transplanted hPMSCs
may fuse with hepatocytes and initiate proliferation
[42-44]. We found fewer ALB- and CK 18-positive cells in
transplanted model pigs. Thus fusion of hPMSCs-derived
hepatocyte-like cells with recipient hepatocytes cannot be
excluded; (2) Homing of transplanted hPMSCs to the reci-
pient liver which may differentiate into normal hepato-
cytes and result in replenishment of the hepatocyte
reservoir [45-47]. Our data revealed that some cells
expressed human ALB and CK 18 in recipient pig livers 5
months after MSCs transplantation; (3) Transplanted
hPMSCs may support and activate liver progenitor cells,
which then further initiate endogenous cell differentiation
Figure 11 H&E staining.( A) Group I (day 4); (B) group II (day 1); (C, D) group III (days 4, 7); (E-L): group IV (days 2, 4, 7, 14, 28, 42, 150, and 155)
(10×); (G-J) liver puncture biopsy specimens.
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Page 15 of 20Figure 12 Immunohistochemistry results of transplanted ALF pig liver samples.( A)N oA L B
+cells were found in liver puncture biopsy
samples 8 weeks after transplantation in Group IV (40×); (B) ALB
+ cells were detected 6 weeks after hPMSCs infusion in the specimen harvested
using an automatic biopsy needle (40×); (C-H) ALB
+cells were observed in three pigs at 5 months (C, E, G, 20×; D, F, H, 40×); (I-P)C K1 8
+cells
were observed in three pigs at 5 months (I, K, M, O, 20×; J, L, N, P, 40×); (Q, S) non-transplanted pig livers served as negative controls for ALB
(Q) and CK 18 (S) staining (20×); (R, T) sections of human liver served as positive controls for ALB (R) and CK 18 (T) staining (40×). It is
noteworthy that almost all ALB
+ or CK18
+cells were adjacent to vascular structures.
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Page 16 of 20and proliferation [48,49]; (4) Transplanted hPMSCs may
secrete multiple cytokines and growth factors that will
inhibit inflammation and accelerate liver restoration
[50-52]. Although hPMSCs proliferation was significantly
decreased after irradiation, these cells may participate in
the repair of damaged liver through pathways 3 and/or 4.
In fact, our LIF and IFN-g data provide evidence support-
ing the immunomodulatory roles of transplanted hPMSCs
[53-56]. hPMSCs transplantation can contribute not only
to hepatocyte repopulation, but also to the improvement
of the internal liver environment.
The number of MSCs transplanted is a key factor, yet
little is known about the optimum dose. Most studies have
used doses of 2-10 million MSCs per kg in small-animal
experiments [57-60]. Some researchers think that the
greater the number of MSCs transplanted, the greater the
therapeutic effect should achieve. In this study, a total
dose of 1.0 × 10
8 hPMSCs in 5 mL saline was safe when
infused into the liver within about 5 min. No embolism
occurred, but the exact correlation between the number of
cells transplanted and their therapeutic effect needs
further investigation.
Choosing an appropriate MSC transplantation route is
vital for cell survival, induction of cell differentiation,
and restoration of liver function. Routine transplantation
paths include those through the spleen, liver, belly cav-
ity, and peripheral and portal veins, each of which has
disadvantages. MSC transplantation through the spleen
is an accepted route, but the transplanted cells usually
grow in nodules and hence contribute little to the
restoration of liver function. MSC transplantation by
hepatic multi-site injection involves the risk of damaging
important liver vessels, causing severe complications
including hemorrhea, portal hypertension, and so on.
MSC transplantation through the belly cavity is simple
but also involves the risk of inducing inflammation and
fever and causing peritonitis and adhesion in the belly
cavity. We compared the effects of transplantation
through peripheral (jugular) and portal veins and our
data suggested that both transplantation routes were
safe, with no portal vein thrombosis. Additionally,
hPMSCs were well distributed in the liver after trans-
plantation through the left branch of the portal vein
under guidance of B-ultrasonography. The long-term
survival rate in the portal vein transplantation group
was significantly higher than that in the peripheral vein
group (66.7% vs. 16.7%). A plausible mechanism may be
the high concentrations of cytokines, growth factors,
and nutrients in the portal vein, which promotes survi-
val, proliferation, and differentiation of transplanted
hPMSCs. In contrast, hPMSCs transplanted through
peripheral paths induce fever and adverse immune reac-
tions. Also, a significant portion of hPMSCs may be lost
when circulating through the lung [61]. Therefore, only
a small portion of transplanted hPMSCs entered the
liver after circulation and immune damage, impeding
the restoration of liver functions.
To determine whether transplanted MSC-derived cells
colonized the pig liver, alu expression was detected by
PCR. The alu repeat sequence is present only in humans
and other primates. It accounts for 10% of the nucleo-
tides in the human genome. The alu sequence is around
300-bp and is the most abundant sequence which
appears at 3-4-kb intervals with moderate repetition.
Because the alu family exhibits species-specificity, it can
be used as a biomarker of human cells [62,63]. In our
study, we amplified the alu sequence to determine
whether hPMSCs were successfully transplanted into the
pig liver. A specific 224-bp sequence was detected at a
number of time points, demonstrating the presence of
transplanted human MSCs in recipient pig livers.
Conclusions
Taken together, our results suggest that MSCs from the
human placenta could be used as an excellent source of
transplanted cells for the repair of liver damage. Portal
vein transplantation under B-ultrasonography guidance
is safe and effective which could restore liver functions
in pigs with liver failure to a substantial extent; however,
the underlying mechanism remains to be further
clarified.
Figure 13 Detection of human-specific hepatic markers by RT-
PCR (A) and alu repeat sequences by PCR (B).( A): Lane 1,
positive control (human liver for ALB and CK 18, hepatocellular
carcinoma liver for AFP; lane 2: Group I as a negative control; lane 3
to 10, pig livers transplanted after 4, 6, 8, 12, 16, and 20 weeks and
5 months (double). Before 5 months, the samples were all obtained
by liver biopsy puncture. Human ALB and CK18 were detected in
the sixth week (lane 4) and the fifth month (lanes 9 and 10). (B):
Lane 1, positive control (human DNA); lanes 2 to 6, Group IV (2, 4, 7,
and 156 days after cell transplantation); lanes 7 and 8, Group III (2
and 4 days after cell transplantation); lanes 9 and 10, Group II (4
and 24 days after cell transplantation); lane 11, Group I (4 days after
GalN infusion).
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AFP: alpha-fetoprotein; ALB: albumin; ALF: acute liver failure; ALP: alkaline
phosphatise; ALT: alanine aminotransferase; APC: allophycocyanin; AST:
aspartate aminotransferase; BSA: bovine serum albumin; CCl4: carbon
tetrachloride; CHE: cholin esterase; CK18: cytokeratin 18; CYP450: cytochrome
P450; DMEM: Dulbecco’s modified eagle medium; EDTA: ethylene diamine
tetraacetic acid; EGF: epidermal growth factor; ELISA: enzyme-linked
immunosorbent assay; ELISpot: enzyme-linked immunospot; FGF: fibroblast
growth factor; FITC: fluorescein isothiocyanate; GalN: D-galactosamine; HE:
hematoxylin and eosin; HGF: hepatocyte growth factor; H2O2: hydrogen
peroxide; hPMSCs: human placental mesenchymal stem cells; IFN: interferon;
IMDM: Iscove’s modified Dulbecco’s medium; ITS: insulin-transferrin-selenium;
LDL: low density lipoprotein; DiI-LDL: 1,19-dioctadecyl-3,3,39,39-
tetramethylllindocarbocyane-low-density lipoprotein; LIF: leukemia inhibitory
factor; LPL: lipoprotein lipase; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; MNCs: mononuclear cells; MSCs: mesenchymal
stem cells; NH4Cl: ammonium chloride; OD: optical density; OPN:
osteopontin; PAS: periodic acid-schiff; PBS: phosphate buffered saline; PBMC:
peripheral blood mononuclear cell; PCR: polymerase chain reactions; PE:
phycoerythrin; TBA: total bile acid; TBIL: total bilirubin.
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